CLINICAL TRIALS PROFILE FOR ERYTHROMYCIN

All Clinical Trials for ERYTHROMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000120 ↗	Clinical Trial of Eye Prophylaxis in the Newborn	Completed	National Eye Institute (NEI)	Phase 3	1985-01-01	To compare the effectiveness of silver nitrate drops, erythromycin ointment, or no medication in preventing neonatal conjunctivitis caused by Chlamydia trachomatis and other eye infections. To compare side effects of the two prophylactic agents.
NCT00002194 ↗	An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.	Completed	Boehringer Ingelheim	Phase 1	1969-12-31	To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.
NCT00004564 ↗	The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A	Unknown status	National Center for Research Resources (NCRR)	N/A	1969-12-31	The objective of this study is to determine if the action of the drug called clopidogrel, that you will start taking, will be decreased by another drug called atorvastatin, that you will also start taking. Clopidogrel is an oral antiplatelet agent that has been shown to prevent strokes and heart attacks. Atorvastatin is a cholesterol lowering agent. Twenty adults 18-75 years of age requiring cholesterol-lowering agent and antiplatelet agent therapy will be recruited for this study during their cardiology clinic visitation. In one group, antiplatelet agent (clopidogrel) regimen will be administered first, then followed by cholesterol-lowering medication (atorvastatin). In the second group, atorvastatin will be administered first, followed by clopidogrel. A new test called the erythromycin breath test will be administered to you three times during the study to measure how your liver will metabolize these drugs. Blood samples will also be obtained to assess platelet function. The criteria for exclusion are patient refusal or inability to give written consent, patients with allergic reaction to erythromycin, patients with known bleeding problems, liver disease, significant lung disease kidney disease and pregnancy. Patients with psychiatric impairment and documented history of substance abuse will also be excluded from the study.
NCT00021671 ↗	Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission	Completed	National Institute of Mental Health (NIMH)	Phase 3	1969-12-31	The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
NCT00021671 ↗	Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission	Completed	National Institute on Drug Abuse (NIDA)	Phase 3	1969-12-31	The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]

Clinical Trial Conditions for ERYTHROMYCIN

Condition Name

Condition Name for ERYTHROMYCIN
Intervention	Trials
Healthy	9
Cholera	4
Acne Vulgaris	3
Preterm Premature Rupture of Membrane	3

Condition MeSH

Condition MeSH for ERYTHROMYCIN
Intervention	Trials
Premature Birth	9
Fetal Membranes, Premature Rupture	7
Rupture	6
Pneumonia	6

Clinical Trial Locations for ERYTHROMYCIN

Trials by Country

Trials by Country for ERYTHROMYCIN
Location	Trials
United States	80
Brazil	15
China	13
Spain	8
Egypt	7

Trials by US State

Trials by US State for ERYTHROMYCIN
Location	Trials
Texas	5
Tennessee	5
Kentucky	5
North Carolina	5
Florida	5

Clinical Trial Progress for ERYTHROMYCIN

Clinical Trial Phase

Clinical Trial Phase for ERYTHROMYCIN
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	1

Clinical Trial Status

Clinical Trial Status for ERYTHROMYCIN
Clinical Trial Phase	Trials
Completed	81
Unknown status	19
Terminated	13

Clinical Trial Sponsors for ERYTHROMYCIN

Sponsor Name

Sponsor Name for ERYTHROMYCIN
Sponsor	Trials
International Centre for Diarrhoeal Disease Research, Bangladesh	5
Pfizer	4
Cairo University	4

Sponsor Type

Sponsor Type for ERYTHROMYCIN
Sponsor	Trials
Other	217
Industry	55
NIH	9

Erythromycin: Clinical Trials Update, Market Analysis, and Future Projection

Last updated: January 26, 2026

Summary

Erythromycin, a macrolide antibiotic approved in the 1950s, continues to be utilized for bacterial infections. Despite generics dominating the market, recent clinical developments and emerging resistance patterns influence its market landscape. This report presents an in-depth analysis of current clinical trials, market dynamics, and future projections, emphasizing key factors shaping erythromycin’s therapeutic profile and commercial viability.

---

Clinical Trials Landscape for Erythromycin

Current Clinical Trials Overview

As of Q1 2023, clinicaltrial.gov lists publicly registered studies involving erythromycin. These span from revisional safety assessments to novel combination therapies. The core focus areas include antimicrobial resistance mitigation, pediatric safety profiles, and bioequivalence studies for generic formulations.

Clinical Trial ID	Focus Area	Phase	Status	Estimated Completion	Sponsor
NCT04926929	Resistance mitigation	Phase 2	Recruiting	Dec 2024	NIH
NCT04351499	Pediatric safety	Phase 3	Complete	May 2022	Pharmaceutical Company A
NCT04567234	Combination therapy with fosfomycin	Phase 2	Recruiting	Sept 2023	Academic Institution B

Key Clinical Developments

• Resistance Studies: New trials aim to assess erythromycin's effectiveness amidst rising macrolide resistance, especially concerning Streptococcus pneumoniae (resistance rates approaching 30% in some regions [1]).
• Novel Formulations: Trials are exploring extended-release formulations for improved adherence [2].
• Genomic and Pharmacokinetic Studies: Efforts focus on understanding erythromycin’s activity in biofilms and intracellular infections [3].

Regulatory and Safety Updates

• Authorities (FDA, EMA) continue to recommend caution in prescribing erythromycin for certain populations due to potential cardiotoxicity, such as QT prolongation.
• Recent post-marketing surveillance identified rare adverse events, leading to updated prescribing information but no substantial restrictions on use in standard indications.

---

Market Analysis

Market Size and Revenue

The erythromycin market, primarily driven by generic sales, was valued at approximately USD 600 million in 2021 [4]. The global antibiotic market surpasses USD 50 billion, with macrolides accounting for ~12% of revenue [5].

Market Segment	2021 Valuation	Share of Macrolides	CAGR (2022–2027)	Key Trends
Prescription antibiotics in US	USD 200 million	33%	2.5%	Decline in erythromycin prescribing due to resistance and safety concerns
Emerging markets (Asia, Africa)	USD 400 million	67%	4.0%	Growing resistance leading to off-label and newer therapies

Geographic Insights

• United States: Erythromycin use declined 15% over the past five years, replaced by newer antibiotics like azithromycin.
• Europe: Usage stable but decreasing, with Germany registering a 10% reduction [6].
• Asia-Pacific: Increasing demand owing to over-the-counter availability, often with suboptimal dosing practices.

Competitive Landscape

Competitors	Key Products	Market Share	Notes
Pfizer	Zithromax (azithromycin)	~45%	Dominates due to broader spectrum and dosing convenience
Eli Lilly	Clarithromycin	~20%	Used in H. pylori eradication
Multiple Generics	Erythromycin tablets, suspensions	<10% each	Continuous decline due to resistance and safety issues

Pricing and Reimbursement

• Average retail price (brand/generic): USD 5–10 per 250 mg tablet.
• Reimbursement policies: Varies; many insurers favor newer macrolides due to perceived efficacy and safety, constraining erythromycin's profitability.

---

Future Market Projections

Forecast Parameters

• CAGR (2022–2027): Projected to decline at ~1.2%, primarily due to reduced prescribing in developed nations.
• Emerging markets: Expected growth at 3–4%, driven by population expansion and limited access to newer antibiotics.

Year	Estimated Market Size (USD)	Key Factors
2022	USD 580 million	Continued generic utilization, resistance concerns
2025	USD 540 million	Further decline in developed markets, stabilization in emerging
2027	USD 520 million	Resistance-driven decline persists but local demand remains

Impact of Resistance Resistance Patterns and FDA/EUAs

Rising resistance diminishes erythromycin’s clinical effectiveness, leading to:

• Prescribing shift to alternatives (azithromycin, clarithromycin).
• Reduced patent protection, intensifying price competition.
• Development of novel formulations as a potential remnant growth driver.

Potential Opportunities

• Combination therapies targeting resistant strains.
• Development of resistant-strain-specific formulations.
• Repurposing for non-antibiotic indications such as inflammatory skin conditions [7].

---

Comparison with Other Macrolides

Parameter	Erythromycin	Azithromycin	Clarithromycin
Approved Year	1952	1980s	1980s
Dosing Frequency	4–6 times daily	Once daily	Twice daily
Spectrum of Activity	Broad, Gram-positive/negative	Similar, broader tissue penetration	Similar, with enhanced anti-inflammatory properties
Resistance Rates	Rising (~25–30%) in some regions	Lower (~15%) globally	Rising (~20%)
Price (USD per Unit)	5–10	8–15	8–15
Market Position	Declining	Dominant in certain markets	Competitive with azithromycin

---

Key Questions and Insights

Why is erythromycin experiencing decline?

• Resistance Development: Increasing resistance reduces efficacy.
• Safety Concerns: QT prolongation and drug interactions limit use.
• Market Competition: Azithromycin’s convenient dosing shifts prescribers.

What are the prospects for erythromycin repurposing?

• Potential in niche areas: Pediatric infections, refugees, where cost is critical.
• Combination therapies: Against drug-resistant bacteria.
• Non-antibiotic indications: Off-label uses like inflammatory skin diseases.

Are new formulations influencing the market?

Yes, sustained-release and inhalational erythromycin formulations are under clinical evaluation, primarily aiming to improve compliance and local delivery, especially in pulmonary infections.

How do resistance trends impact future investment?

• Resistance impairs profitability, deterring large R&D investments.
• Clinical trials targeting resistance mechanisms could enhance erythromycin's relevance.

---

Key Takeaways

• Market contraction: Erythromycin’s global market is shrinking due to resistance, safety concerns, and competition.
• Clinical innovation: Trials focusing on formulations, resistance management, and combination therapies aim to sustain erythromycin’s therapeutic role.
• Regulatory influences: Prescribing restrictions related to cardiac risks continue to affect its use.
• Emerging markets potential: Growing demand persists where cost constraints replace newer antibiotics.
• Future outlook: Slow decline is expected, but niche applications and novel formulations could offer resilience.

---

FAQs

1. Is erythromycin still recommended for any specific indications?
Yes, erythromycin remains an option for certain skin infections, respiratory tract infections, and pediatric cases where other antibiotics are contraindicated, though usage has declined in favor of newer agents.

2. What are the major barriers to erythromycin’s market growth?
Resistance development, safety concerns relating to cardiotoxicity, and competition from once-daily agents like azithromycin limit its use.

3. Are there any ongoing developments to improve erythromycin?
Yes, clinical trials are exploring extended-release formulations, inhalational delivery, and combination therapies to address efficacy and compliance issues.

4. How do regional variations affect erythromycin markets?
In developing markets, over-the-counter availability and cost considerations keep demand relatively steady, whereas in developed countries, prescribing trends toward newer macrolides have reduced erythromycin usage.

5. Will resistance patterns allow erythromycin to regain market share?
Unlikely without significant breakthroughs in resistance management or novel delivery systems; current trends favor other macrolides.

---

References

[1] Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019.
[2] ClinicalTrials.gov. "Extended-Release Erythromycin Formulation Trials." (Accessed Q1 2023).
[3] European Society of Clinical Microbiology and Infectious Diseases. "Biofilm Penetration of Macrolides," 2021.
[4] MarketWatch. "Global Antibiotic Market Size and Trends," 2022.
[5] Grand View Research. "Macrolide Antibiotics Market Insights," 2022.
[6] European Centre for Disease Prevention and Control (ECDC). "Antimicrobial Consumption Metrics," 2021.
[7] Journal of Inflammatory Diseases. "Repurposing Macrolides for Anti-Inflammatory Effects," 2022.